UNASSIGNED:与当前常用的预处理方法相比,超声造影引导下聚桂醇注射液(CEUSL)硬化治疗剖宫产瘢痕妊娠(CSP)的疗效尚不明确.本研究旨在探讨CEUSL与明胶海绵子宫动脉栓塞术(UAE)及UAE联合甲氨蝶呤(UAEM)治疗CSP的临床疗效及安全性,以预防术后刮宫时大出血。
未经证实:64例患者被分为CEUSL(n=20),阿联酋(n=22),和UAEM(n=22)组。所有CSP患者在CEUSL术后行刮宫及宫腔镜检查,阿联酋,或UAEM预处理。分析预处理后的疗效和安全性指标。
UNASSIGNED:与阿联酋相比,CEUSL组的预处理时间[95%置信区间(CI):31.92-39.28]和住院费用(95%CI:7,852.32-9,063.23)显着降低(95%CI:53.55-59.99%和95%CI:901.42-5166.63%分别为4.13,UEMCEUSL组24小时后β人绒毛膜促性腺激素(β-hCG)百分比降低,住院时间显着降低(95%CI:0.65-0.70和95%CI:3.32-4.58天,分别)与阿联酋(95%CI:0.67-0.74和95%CI:4.06-5.84)或UAEM(95%CI:0.62-0.68和95%CI:4.12-5.88)组(P<0.05)。预处理后,发热患者明显较少(P<0.05)(95%CI:-0.52~-0.093),盆腔疼痛(95%CI:-0.427至-0.018),白细胞计数增加(95%CI:-0.359至0.040),与UAE或UAEM组相比,CEUSL组的超敏C反应蛋白(hs-CRP)升高(95%CI:-0.572至-0.118)。在后续行动中,所有患者月经恢复正常,在超声成像或后遗症中没有残留的孕囊。
未经评估:预处理程序在技术上都是成功的,在不同的预处理程序中具有良好的效果。与有或没有甲氨蝶呤的阿联酋相比,CEUSL对于CSP的预处理可能同样有效和安全,不良反应少,预处理时间和住院时间短。
UNASSIGNED: Compared with the current commonly used pretreatment approaches, the therapeutic effect of contrast-enhanced ultrasound-guided sclerotherapy with lauromacrogol injection (CEUSL) on cesarean scar pregnancy (CSP) is not clear. This study aimed to investigate the clinical efficacy and safety of CEUSL compared with gelatin sponge uterine artery embolization (UAE) and UAE combined with methotrexate (UAEM) in the pretreatment of CSP to prevent massive bleeding during subsequent curettage.
UNASSIGNED: Sixty-four patients were divided into the CEUSL (n=20), UAE (n=22), and UAEM (n=22) groups. All patients with CSP underwent curettage and hysteroscopy after CEUSL, UAE, or UAEM pretreatment. The efficacy and safety indicators after pretreatment were analyzed.
UNASSIGNED: Time for pretreatment [95% confidence interval (CI): 31.92-39.28] and hospitalization cost (95% CI: 7,852.32-9,063.23) were significantly decreased in the CEUSL group compared with that in the UAE (95% CI: 53.55-59.99% and 95% CI: 12,901.42-15,166.63, respectively) and the UAEM group (95% CI: 52.90-58.83 and 95% CI: 11,324.66-13,302.69, respectively; P<0.001). The beta human chorionic gonadotropin (β-hCG) percentage decrease 24 hours later and the hospital stay were significantly decreased in the CEUSL group (95% CI: 0.65-0.70 and 95% CI: 3.32-4.58 days, respectively) compared with those in the UAE (95% CI: 0.67-0.74 and 95% CI: 4.06-5.84, respectively) or UAEM (95% CI: 0.62-0.68 and 95% CI: 4.12-5.88, respectively) groups (P<0.05). After pretreatment, there were significantly fewer patients (P<0.05) with fever (95% CI: -0.52 to -0.093), pelvic pain (95% CI: -0.427 to -0.018), increased white blood cell count (95% CI: -0.359 to 0.040), and hypersensitive C-reactive protein (hs-CRP) elevation (95% CI: -0.572 to -0.118) in the CEUSL group than in the UAE or UAEM groups. At follow-up, all patients resumed normal menstruation, with no residual gestational sac on ultrasound imaging or sequel.
UNASSIGNED: The pretreatment procedures were all technically successful, with good outcomes in different pretreatment procedures. Compared with UAE with or without methotrexate, CEUSL may be as effective and safe for pretreatment of CSP, with fewer adverse effects and shorter pretreatment time and hospital stay.